Serum pro-brain natriuretic peptide correlates with optical coherence tomography indices in diabetic retinopathy.

Purpose: Serum pro-brain natriuretic peptide (BNP) is a 108-amino-acid prohormone that inhibits vascular endothelial growth factor (VEGF) secretion, protecting pericytes from cell death and decreasing retinal vascularization. The purpose of this study was to investigate the correlation of serum pro-BNP with optical coherence tomography (OCT) indices in diabetic retinopathy.

Methods: This cross-sectional study investigated 96 consecutive subjects aged between 40 and 65 years: controls n = 24, no diabetic retinopathy (NoDR) n = 24, non-proliferative diabetic retinopathy (NPDR) n = 24, and proliferative diabetic retinopathy (PDR) n = 24.

Harnessing carbon electrodes in molecular junctions: progress and challenges in device engineering.

The relentless pursuit of miniaturization and enhanced functionality in electronic devices has driven researchers to explore innovative approaches. Carbon electrode-based molecular junctions (MJs) have emerged as a promising frontier in the quest for next-generation electronics. This review provides a comprehensive overview of the current state of research on carbon-based MJs for practical devices, focusing on their unique properties, such as charge transport phenomena, fabrication methods, and potential applications in revolutionizing electronic components.

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Anemia in Chronic Kidney Disease: Guidelines for South Asia.

This guideline addresses the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in patients >18 years with chronic kidney disease (CKD) and anemia in South Asia (Bangladesh, Bhutan, Nepal, India, Pakistan, Sri Lanka). It also summarizes recommendations for anemia treatment for individual HIF-PHI molecules under two categories: dialysis-dependent and non-dialysis-dependent CKD patients. The recommendations do not apply to pediatric (≤12 years) and adolescent (12 to 18) patients or those with primary anemia or anemia secondary to other causes such as blood loss, cancer (any type), polycystic kidney disease and infectious diseases.